$RDHL

RedHill Biopharma (RDHL) announced a $2.9M grant for trials of its drug opaganib combined with CAR T-cell therapy for multiple myeloma. The University of Oklahoma will conduct the trials, with RedHill providing opaganib. Preclinical studies suggest the combination may improve treatment outcomes. Opaganib targets the SPHK2 protein, potentially enhancing immune cell activity against cancer.

U.S. stocks declined midweek, with small caps hit hardest as 10-year Treasury yields rose to 5.24%. McCormick (MKC) reported Q3 sales up 17.4%, EPS $0.36. Conagra (CAG) saw Q1 sales down 1.4%, EPS up 5.1%. WTW (WTW) noted commercial property rate declines. RedHill (RDHL) outlined portfolio reset. Recon (RCON) reported 65.8% revenue growth, narrowed losses.

U.S. stocks ended the week lower, with the Dow down 1.93%, S&P 500 down 1.25%, and Nasdaq down 0.90%. The Russell 2000 underperformed, falling 1.16%. The 10-year Treasury yield rose 6 basis points to 5.24%. Earnings reports from McCormick (MKC), Conagra (CAG), Recon Technology (RCON), Yiren Digital (YRD), and RedHill Biopharma (RDHL) were released.

RedHill Biopharma Ltd. (RDHL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ​ ​ Press Release RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results ​ Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota ® and Clenpiq ® , two established FDA-approved gastrointe

RedHill Biopharma reported H1 2026 results, highlighting a strategic portfolio reset. The company acquired commercial rights to Rebyota® and Clenpiq® for $12M, funded by the $18M sale of Talicia®. These FDA-approved GI drugs generated $37.5M in 2025 net sales. RedHill aims to grow revenues and expand its pipeline, with ongoing R&D in oncology and GI indications. The company's CEO emphasized improved liquidity and growth potential. (350 characters)

RedHill Biopharma (RDHL) acquired global rights to Rebyota and U.S. rights to Clenpiq from Ferring for $12M upfront, with royalties of 5-20%. The products had $37.5M combined U.S. sales in 2025. Ferring retains manufacturing, while RedHill handles commercialization. Success depends on sales growth and supply reliability.

RedHill Biopharma (RDHL) acquired exclusive commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals, receiving $12M upfront. The deal expands RDHL's gastrointestinal drug portfolio. RDHL's P/S ratio is 0.64x, below its 10.8x historical median, indicating market skepticism. The company has a GF Score of 25/100, signaling financial and operational challenges, with a distress-level Altman Z-Score of -24.34.

RedHill Biopharma (RDHL) shares rose 64% after announcing the sale of its Talicia business to Apotex Health Corp. for $18M upfront and up to $35M in milestones. The stock traded at $1.08, up from a 52-week low of $0.57.

RedHill Biopharma (RDHL) sold its 70% stake in Talicia to Apotex (APTX) for $18M upfront and up to $35M in milestones. The deal strengthens RedHill's liquidity and funds its commercial expansion. Talicia treats H. pylori infections, a cause of gastric cancer and ulcers.

RedHill Biopharma completed a joint venture with Cumberland Pharmaceuticals on October 17, 2025, by selling a 30% equity stake in Talicia Holdings Inc. This deal involved Cumberland investing $4 million for joint control of THI, leading RedHill to deconsolidate THI operations and classify them as discontinued. RedHill has since filed unaudited pro forma financials to show the impact of this new financial structure and joint venture accounting on its historical results.